Orthobiologics

The research is investigating amniotic tissue as a potential treatment for chronic musculoskeletal pain and function disorders. ...

Canada will be the first commercial market to launch i-FACTOR+ Matrix. The technology is currently being studied in an FDA...

This U.S. Phase II trial intends to demonstrate safety and efficacy of Fibrin-PTH in patients undergoing a single-level TLIF procedure....

OsteoFlo NanoPutty bone graft features the world’s first quadphasic synthetic bone graft particles with nano-surface technology. ...

The company announced the U.S. commercial launch of the Matriform Si, a silicated synthetic bone graft substitute designed and cleared...

The IDE Supplement allows for a reduction in the number of patients required to be enrolled in the ASPIRE IDE...

The patents cover combinations of polymers and granular materials and further expand Kuros' patent portfolio relating to its MagnetOs product....

The transitional pass-through payment reimburses outpatient centers and ASCs for incremental cost of AUGMENT in hindfoot and ankle fusion....

The limited market release of Tempest Allograft Bone Matrix marks Spine Wave's entry into the spinal biologics market....

The product expands Aziyo's regenerative medicine portfolio and leverages proprietary processing to protect and preserve native bone cells....